UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 110

Sortiert nach

No Significant Effect of COVID-19 on Immunological and Virological Parameters in Patients With HIV-1 Infection

Journal of acquired immune deficiency syndromes (1999), 2020-09, Vol.85 (1), p.e6

2020

Volltextzugriff (PDF)

The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis

Autoimmune Diseases, 2013-01, Vol.2013, p.326258-7

2013

Volltextzugriff (PDF)

COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection

Journal of acquired immune deficiency syndromes (1999), 2021-01, Vol.86 (1), p.e15

2021

Volltextzugriff (PDF)

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

Infection, 2021-04, Vol.49 (2), p.333-337

2021

Volltextzugriff (PDF)

Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir

Infection, 2020-04, Vol.48 (2), p.213-221

2020

Volltextzugriff (PDF)

Pillars of long-term antiretroviral therapy success

Pharmacological research, 2023-10, Vol.196, p.106898-106898, Article 106898

2023

Volltextzugriff (PDF)

Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV

Journal of cachexia, sarcopenia and muscle, 2021-12, Vol.12 (6), p.1613-1616

2021

Volltextzugriff (PDF)

Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study

Antiviral therapy, 2016-01, Vol.21 (3), p.217-224

2016

Volltextzugriff (PDF)

Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy

Clinical and experimental nephrology, 2019-11, Vol.23 (11), p.1272-1279

2019

Volltextzugriff (PDF)

RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men

Journal of medical virology, 2007-10, Vol.79 (10), p.1446-1454

2007

Volltextzugriff (PDF)

Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy

HIV research & clinical practice, 2019-11, Vol.20 (6), p.131-139

2019

Volltextzugriff (PDF)

Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz

Current HIV research, 2016-01, Vol.14 (1), p.61

2016

Volltextzugriff (PDF)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

BMC infectious diseases, 2012-02, Vol.12 (1), p.38-38, Article 38

2012

Volltextzugriff (PDF)

HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells

Retrovirology, 2011-05, Vol.8 (1), p.40-40, Article 40

2011

Volltextzugriff (PDF)

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

AIDS (London), 2022-01, Vol.36 (1), p.153-155

2022

Volltextzugriff (PDF)

Recommendations for Evaluation and Management of Bone Disease in HIV

Clinical infectious diseases, 2015-04, Vol.60 (8), p.1242-1251

2015

Volltextzugriff (PDF)

Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients

Journal of antimicrobial chemotherapy, 2019-03, Vol.74 (3), p.731-738

2019

Volltextzugriff (PDF)

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy

Journal of antimicrobial chemotherapy, 2020-11, Vol.75 (11), p.3327-3333

2020

Volltextzugriff (PDF)

HIV policy in Italy and recommendations across the HIV care continuum

Le infezioni in medicina, 2020-03, Vol.28 (1), p.17-28

2020

Volltextzugriff (PDF)

Prevalence of transmitted drug resistance mutations among newly diagnosed HIV‐1‐infected patients in a large teaching hospital of the Northern Italy

Journal of medical virology, 2020-08, Vol.92 (8), p.929-931

2020

Volltextzugriff (PDF)

Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome

Infectious diseases (London, England), 2021-02, Vol.53 (2), p.81-88

2021

Volltextzugriff (PDF)

Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

The Journal of infectious diseases, 2015-01, Vol.211 (2), p.178-186

2015

Volltextzugriff (PDF)

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

Infectious diseases (London, England), 2020-04, Vol.52 (4), p.249-256

2020

Volltextzugriff (PDF)

Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients

AIDS (London), 2017-03, Vol.31 (5), p.681-688

2017

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(110)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

No Significant Effect of COVID-19 on Immunological and Virological Parameters in Patients With HIV-1 Infection

The Role of Simvastatin in the Therapeutic Approach of Rheumatoid Arthritis

COVID-19 Outcomes in Patients With Uncontrolled HIV-1 Infection

COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy

Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir

Pillars of long-term antiretroviral therapy success

Benefits of a 12 week physical activity programme on muscle and bone health in people living with HIV

Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study

Prevalence of chronic kidney disease among HIV-1-infected patients receiving a combination antiretroviral therapy

PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection

RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men

Vitamin D insufficiency is associated with subclinical atherosclerosis in HIV-1-infected patients on combination antiretroviral therapy

Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz

HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

Recommendations for Evaluation and Management of Bone Disease in HIV

Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients

Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy

HIV policy in Italy and recommendations across the HIV care continuum

Prevalence of transmitted drug resistance mutations among newly diagnosed HIV‐1‐infected patients in a large teaching hospital of the Northern Italy

Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome

Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Non-AIDS-Defining Events in a Large Cohort of HIV-Infected Patients

No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up

Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients

Suchergebnisse filtern